TVTX logo

Travere Therapeutics (TVTX) EBIT

Annual EBIT

-$364.78 M
-$97.88 M-36.67%

December 31, 2023


Summary


Performance

TVTX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXprofitabilitymetrics:

Quarterly EBIT

-$52.06 M
+$14.72 M+22.04%

September 30, 2024


Summary


Performance

TVTX Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXprofitabilitymetrics:

TTM EBIT

-$337.51 M
+$34.35 M+9.24%

September 30, 2024


Summary


Performance

TVTX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXprofitabilitymetrics:

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

TVTX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-36.7%+39.3%+7.5%
3 y3 years-114.9%+37.1%-12.1%
5 y5 years-296.3%+37.1%-12.1%

TVTX EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-128.6%at lowat high+60.9%-71.2%+16.5%
5 y5-year-185.8%at low-292.0%+60.9%-332.5%+16.5%
alltimeall time-422.2%at low-135.9%+60.9%-368.6%+16.5%

Travere Therapeutics EBIT History

DateAnnualQuarterlyTTM
Sep 2024
-
-$52.06 M(-22.0%)
-$337.51 M(-9.2%)
Jun 2024
-
-$66.78 M(-49.8%)
-$371.86 M(-8.0%)
Mar 2024
-
-$132.97 M(+55.1%)
-$404.11 M(+10.8%)
Dec 2023
-$364.78 M(+36.7%)
-$85.71 M(-0.8%)
-$364.77 M(+0.8%)
Sep 2023
-
-$86.41 M(-12.7%)
-$361.78 M(+1.5%)
Jun 2023
-
-$99.02 M(+5.8%)
-$356.46 M(+10.9%)
Mar 2023
-
-$93.64 M(+13.2%)
-$321.45 M(+6.7%)
Dec 2022
-$266.89 M(+67.3%)
-$82.72 M(+2.0%)
-$301.21 M(-0.5%)
Sep 2022
-
-$81.09 M(+26.7%)
-$302.66 M(+20.0%)
Jun 2022
-
-$64.01 M(-12.8%)
-$252.27 M(+13.4%)
Mar 2022
-
-$73.40 M(-12.8%)
-$222.37 M(+12.8%)
Dec 2021
-$159.54 M(-6.0%)
-$84.16 M(+174.2%)
-$197.20 M(-14.4%)
Sep 2021
-
-$30.70 M(-10.0%)
-$230.37 M(+6.0%)
Jun 2021
-
-$34.11 M(-29.3%)
-$217.43 M(+6.2%)
Mar 2021
-
-$48.23 M(-58.9%)
-$204.69 M(+20.6%)
Dec 2020
-$169.74 M(+33.0%)
-$117.33 M(+560.7%)
-$169.74 M(+117.5%)
Sep 2020
-
-$17.76 M(-16.9%)
-$78.04 M(-15.9%)
Jun 2020
-
-$21.37 M(+60.9%)
-$92.75 M(-11.8%)
Mar 2020
-
-$13.28 M(-48.2%)
-$105.19 M(-17.6%)
Dec 2019
-$127.62 M(+38.6%)
-$25.63 M(-21.1%)
-$127.62 M(+22.1%)
Sep 2019
-
-$32.47 M(-4.0%)
-$104.48 M(-15.5%)
Jun 2019
-
-$33.81 M(-5.3%)
-$123.59 M(+11.5%)
Mar 2019
-
-$35.71 M(+1332.5%)
-$110.88 M(+20.3%)
Dec 2018
-$92.06 M(+70.7%)
-$2.49 M(-95.2%)
-$92.16 M(-7.5%)
Sep 2018
-
-$51.57 M(+144.3%)
-$99.60 M(+50.0%)
Jun 2018
-
-$21.11 M(+24.2%)
-$66.39 M(+11.1%)
Mar 2018
-
-$16.99 M(+71.1%)
-$59.78 M(+7.1%)
Dec 2017
-$53.94 M
-$9.93 M(-45.9%)
-$55.81 M(+3.3%)
Sep 2017
-
-$18.36 M(+26.6%)
-$54.04 M(-18.2%)
Jun 2017
-
-$14.50 M(+11.3%)
-$66.03 M(-8.5%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$13.02 M(+59.5%)
-$72.18 M(+36.6%)
Dec 2016
-$52.85 M(-146.7%)
-$8.16 M(-73.1%)
-$52.85 M(-7.8%)
Sep 2016
-
-$30.35 M(+47.0%)
-$57.35 M(-148.6%)
Jun 2016
-
-$20.65 M(-427.3%)
$118.03 M(+1.7%)
Mar 2016
-
$6.31 M(-149.8%)
$116.09 M(+2.5%)
Dec 2015
$113.22 M(-241.9%)
-$12.66 M(-108.7%)
$113.22 M(-9.9%)
Sep 2015
-
$145.03 M(-742.0%)
$125.63 M(-461.5%)
Jun 2015
-
-$22.59 M(-758.2%)
-$34.75 M(+4829.6%)
Mar 2015
-
$3.43 M(-1500.8%)
-$705.00 K(-97.3%)
Dec 2014
-$79.81 M(+222.2%)
-$245.00 K(-98.4%)
-$26.20 M(-12.9%)
Sep 2014
-
-$15.35 M(-234.0%)
-$30.08 M(+51.3%)
Jun 2014
-
$11.46 M(-151.9%)
-$19.88 M(-45.4%)
Mar 2014
-
-$22.06 M(+434.8%)
-$36.44 M(+124.0%)
Dec 2013
-$24.77 M(-18.1%)
-$4.13 M(-20.0%)
-$16.27 M(+33.9%)
Sep 2013
-
-$5.15 M(+1.1%)
-$12.14 M(+73.7%)
Jun 2013
-
-$5.10 M(+170.5%)
-$6.99 M(+269.0%)
Mar 2013
-
-$1.89 M(>+9900.0%)
-$1.89 M(>+9900.0%)
Dec 2012
-$30.26 M(>+9900.0%)
-
-
Nov 2012
-
-$3200.00(+6.7%)
-$13.00 K(+1.6%)
Aug 2012
-
-$3000.00(0.0%)
-$12.80 K(0.0%)
May 2012
-
-$3000.00(-21.1%)
-$12.80 K(0.0%)
Feb 2012
-
-$3800.00(+26.7%)
-$12.80 K(+1.6%)
Feb 2012
-$12.80 K(+0.8%)
-
-
Nov 2011
-
-$3000.00(0.0%)
-$12.60 K(-0.8%)
Aug 2011
-
-$3000.00(0.0%)
-$12.70 K(-22.1%)
May 2011
-
-$3000.00(-16.7%)
-$16.30 K(-18.1%)
Feb 2011
-$12.70 K
-$3600.00(+16.1%)
-$19.90 K(+22.1%)
Nov 2010
-
-$3100.00(-53.0%)
-$16.30 K(+23.5%)
Aug 2010
-
-$6600.00(0.0%)
-$13.20 K(+100.0%)
May 2010
-
-$6600.00
-$6600.00

FAQ

  • What is Travere Therapeutics annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Travere Therapeutics?
  • What is Travere Therapeutics annual EBIT year-on-year change?
  • What is Travere Therapeutics quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Travere Therapeutics?
  • What is Travere Therapeutics quarterly EBIT year-on-year change?
  • What is Travere Therapeutics TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Travere Therapeutics?
  • What is Travere Therapeutics TTM EBIT year-on-year change?

What is Travere Therapeutics annual earnings before interest & taxes?

The current annual EBIT of TVTX is -$364.78 M

What is the all time high annual EBIT for Travere Therapeutics?

Travere Therapeutics all-time high annual earnings before interest & taxes is $113.22 M

What is Travere Therapeutics annual EBIT year-on-year change?

Over the past year, TVTX annual earnings before interest & taxes has changed by -$97.88 M (-36.67%)

What is Travere Therapeutics quarterly earnings before interest & taxes?

The current quarterly EBIT of TVTX is -$52.06 M

What is the all time high quarterly EBIT for Travere Therapeutics?

Travere Therapeutics all-time high quarterly earnings before interest & taxes is $145.03 M

What is Travere Therapeutics quarterly EBIT year-on-year change?

Over the past year, TVTX quarterly earnings before interest & taxes has changed by +$33.65 M (+39.26%)

What is Travere Therapeutics TTM earnings before interest & taxes?

The current TTM EBIT of TVTX is -$337.51 M

What is the all time high TTM EBIT for Travere Therapeutics?

Travere Therapeutics all-time high TTM earnings before interest & taxes is $125.63 M

What is Travere Therapeutics TTM EBIT year-on-year change?

Over the past year, TVTX TTM earnings before interest & taxes has changed by +$27.26 M (+7.47%)